Clinical trials
Castration Resistant Prostatic Cancer clinical trials
Below are recruiting castration resistant prostatic cancer clinical trials, each written for real people, not researchers. We’re tracking 290 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07288359RecruitingPhase 1/Phase 2
Study of GVV858 for HR+/HER2- breast cancer and other solid tumors
This trial is testing a new drug, GVV858, either alone or with hormone therapy, for people with HR+/HER2- advanced breast cancer or certain other advanced solid tumors. It may be an option if standard treatments are no longer working or available.
Atlanta, GeorgiaAges 18 years+ - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Los Angeles, CaliforniaAges 18 years+ - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT07258407RecruitingPhase 1/Phase 2
TD001 for men with PSMA-positive metastatic prostate cancer
This trial tests a new drug, TD001, in men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It aims to see if TD001 is safe and effective against tumors that show a specific marker called PSMA.
New Haven, ConnecticutAges 18 years+ - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07244393RecruitingPhase 1
Combination therapy for advanced prostate cancer
This trial tests a new combination therapy for advanced prostate cancer that has stopped responding to standard hormone treatments. It combines a radioactive targeted treatment (Lutetium-177 DGUL) with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors and slow the cancer's growth.
SeoulAges 19 years+ - NCT07240857Enrolling by invitationEarly Phase 1
CAR-T cell injection for advanced prostate cancer
This trial tests a new treatment called ACT#001 CAR-T cells, given as a local injection, for prostate cancer that has stopped responding to hormone therapy. It aims to see if this therapy is safe and can help shrink tumors.
Hangzhou, ZhejiangAges 18 years+ - NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Chandler, ArizonaAges 18 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Goodyear, ArizonaAges 18 years+ - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT03903835RecruitingPhase 3
Biomarker-guided treatment for metastatic prostate cancer
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
AalstAges 18 years+ - NCT06480110RecruitingPhase 1/Phase 2
Ebastine plus docetaxel for advanced prostate cancer
This trial tests if combining the allergy drug ebastine with the chemotherapy docetaxel can help men with advanced prostate cancer that has stopped responding to hormone therapy. It may offer a new treatment option for those whose cancer is still growing.
CopenhagenAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Anchorage, AlaskaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
Targeted radiation therapy for advanced solid tumors
This study tests a new radioactive treatment (177Lu-BetaBart) for people with certain advanced solid tumors that have stopped responding to standard treatments. It aims to see if this targeted therapy can slow or stop tumor growth.
Dothan, AlabamaAges 18 years+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
Sarasota, FloridaAges 18 years+ - NCT07192614RecruitingPhase 1/Phase 2
Study of AZD6621 for men with advanced prostate cancer
This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.
Orlando, FloridaAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07156045RecruitingEarly Phase 1
Study of donor NK cells targeting PSMA for advanced prostate cancer
This trial tests a new treatment using natural killer cells from a healthy donor that are designed to find and attack prostate cancer cells that have a protein called PSMA. It may help men with advanced prostate cancer that has stopped responding to hormone therapy.
Beijing, Beijing MunicipalityAges 18 years+
Hear when a new Castration Resistant Prostatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for castration resistant prostatic cancer?
- Yes. Clin2 currently lists 290 recruiting castration resistant prostatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a castration resistant prostatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a castration resistant prostatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Castration-resistant Prostate Cancer
- Prostatic Neoplasms, Castration-Resistant
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Non Small Cell Lung Cancer
- Platinum-resistant Ovarian Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.